Shares of Hoth Therapeutics, Inc. (HOTH) are surging over 50% on Wednesday after the biopharmaceutical company said it has signed a production deal for cancer treatment.
HOTH is currently trading at $2.48, up $0.84 or 51.22%, on the Nasdaq.
Hoth Therapeutics announced that it has signed a production agreement for both GLP and GMP materials associated with HT-001 with Tergus Pharma for its novel cancer treatment drug, HT-001.
Recently, Hoth requested a Pre-Investigational New Drug meeting to the FDA to discuss a proposed drug development program for the novel treatment.
HT-001 is a topical formulation designed for the treatment of patients with mild to moderate rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor inhibitor therapy.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.